N.S. Patil, B.Y. Nabet, S. Müller, H. Koeppen, W. Zou, J. Giltnane, A. Au-Yeung, S. Srivats, J.H. Cheng, C. Takahashi, P.E. de Almeida, A.S. Chitre, J.L. Grogan, L. Rangell, S. Jayakar, M. Peterson, A.W. Hsia, W.E. O’Gorman, M. Ballinger, R. Banchereau, D.S. Shames, Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell. 40, 289–300e284 (2022)
Article CAS PubMed Google Scholar
S.R. Yang, A.M. Schultheis, H. Yu, D. Mandelker, M. Ladanyi, R. Büttner, Precision medicine in non-small cell lung cancer: current applications and future directions. Semin Cancer Biol. 84, 184–198 (2022)
Article CAS PubMed Google Scholar
D.S. Hong, M.G. Fakih, J.H. Strickler, J. Desai, G.A. Durm, G.I. Shapiro, G.S. Falchook, T.J. Price, A. Sacher, C.S. Denlinger, Y.J. Bang, G.K. Dy, J.C. Krauss, Y. Kuboki, J.C. Kuo, A.L. Coveler, K. Park, T.W. Kim, F. Barlesi, P.N. Munster, S.S. Ramalingam, T.F. Burns, F. Meric-Bernstam, H. Henary, J. Ngang, G. Ngarmchamnanrith, J. Kim, B.E. Houk, J. Canon, J.R. Lipford, G. Friberg, P. Lito, R. Govindan, B.T. Li, KRAS(G12C) inhibition with Sotorasib in Advanced Solid Tumors. N Engl. J. Med. 383, 1207–1217 (2020)
Article CAS PubMed PubMed Central Google Scholar
Y. Cui, W. Fang, C. Li, K. Tang, J. Zhang, Y. Lei, W. He, S. Peng, M. Kuang, H. Zhang, L. Chen, D. Xu, C. Tang, W. Zhang, Y. Zhu, W. Jiang, N. Jiang, Y. Sun, Y. Chen, H. Wang, Y. Lai, S. Li, Q. He, J. Zhou, Y. Zhang, M. Lin, H. Chen, C. Zhou, C. Wang, J. Wang, X. Zou, L. Wang, Z. Ke, Development and validation of a Novel signature to predict overall survival in “Driver Gene-negative” lung adenocarcinoma (LUAD): results of a Multicenter Study. Clin. Cancer Res. 25, 1546–1556 (2019)
Y. Chai, X. Wu, H. Bai, J. Duan, Combined immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line treatment of driver-gene-negative non-squamous non-small cell Lung Cancer: an updated systematic review and network Meta-analysis, J. Clin. Med., 11, (2022)
W.J. Liu, Y. Du, R. Wen, M. Yang, J. Xu, Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol. Ther. 206, 107438 (2020)
Article CAS PubMed Google Scholar
N.H. Hanna, B.J. Schneider, S. Temin, S. Jr. Baker, J. Brahmer, P.M. Ellis, L.E. Gaspar, R.Y. Haddad, P.J. Hesketh, D. Jain, I. Jaiyesimi, D.H. Johnson, N.B. Leighl, T. Phillips, G.J. Riely, A.G. Robinson, R. Rosell, J.H. Schiller, N. Singh, D.R. Spigel, J.O. Stabler, J. Tashbar, G. Masters, Therapy for Stage IV Non-Small-Cell Lung Cancer without driver alterations: ASCO and OH (CCO) Joint Guideline Update. J. Clin. Oncol. 38, 1608–1632 (2020)
X. Si, R. Pan, S. Ma, L. Li, L. Liang, P. Zhang, Y. Chu, H. Wang, M. Wang, X. Zhang, L. Zhang, Genomic characteristics of driver genes in chinese patients with non-small cell lung cancer. Thorac. Cancer. 12, 357–363 (2021)
Article CAS PubMed Google Scholar
J. Mazieres, A. Drilon, A. Lusque, L. Mhanna, A.B. Cortot, L. Mezquita, A.A. Thai, C. Mascaux, S. Couraud, R. Veillon, M. Van den Heuvel, J. Neal, N. Peled, M. Früh, T.L. Ng, V. Gounant, S. Popat, J. Diebold, J. Sabari, V.W. Zhu, S.I. Rothschild, P. Bironzo, A. Martinez-Marti, A. Curioni-Fontecedro, R. Rosell, M. Lattuca-Truc, M. Wiesweg, B. Besse, B. Solomon, F. Barlesi, R.D. Schouten, H. Wakelee, D.R. Camidge, G. Zalcman, S. Novello, S.I. Ou, J. Milia, O. Gautschi, Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann. Oncol. 30, 1321–1328 (2019)
Article CAS PubMed PubMed Central Google Scholar
M. Russano, A. Cortellini, R. Giusti, A. Russo, F. Zoratto, F. Rastelli, A. Gelibter, R. Chiari, O. Nigro, M. De Tursi, S. Bracarda, S. Gori, F. Grossi, M. Bersanelli, L. Calvetti, V. Di Noia, M. Scartozzi, M. Di Maio, P. Bossi, A. Falcone, F. Citarella, F. Pantano, C. Ficorella, M. Filetti, V. Adamo, E. Veltri, F. Pergolesi, M.A. Occhipinti, L. Nicolardi, A. Tuzi, P. Di Marino, S. Macrini, A. Inno, M. Ghidini, S. Buti, G. Aprile, E. Lai, M. Audisio, S. Intagliata, R. Marconcini, D. Brocco, G. Porzio, M. Piras, E. Rijavec, F. Simionato, C. Natoli, M. Tiseo, B. Vincenzi, G. Tonini, D. Santini, Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunol. Immunother. 71, 865–874 (2022)
W.Y. Xia, W. Feng, C.C. Zhang, Y.J. Shen, Q. Zhang, W. Yu, X.W. Cai, X.L. Fu, Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review. Transl Lung Cancer Res. 9, 2120–2136 (2020)
Article CAS PubMed PubMed Central Google Scholar
L. Khoja, D. Day, T. Wei-Wu, L.L. Chen, A.R. Siu, Hansen, Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol. 28, 2377–2385 (2017)
Article CAS PubMed Google Scholar
G. Kara, G.A. Calin, B. Ozpolat, RNAi-based therapeutics and tumor targeted delivery in cancer. Adv. Drug Deliv Rev. 182, 114113 (2022)
Article CAS PubMed Google Scholar
N. Jiang, C. Zou, Y. Zhu, Y. Luo, L. Chen, Y. Lei, K. Tang, Y. Sun, W. Zhang, S. Li, Q. He, J. Zhou, Y. Chen, J. Luo, W. Jiang, Z. Ke, HIF-1ɑ-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and notch signaling. Theranostics. 10, 2553–2570 (2020)
Article CAS PubMed PubMed Central Google Scholar
A.A. Sayyed, P. Gondaliya, P. Bhat, M. Mali, N. Arya, A. Khairnar, K. Kalia, Role of miRNAs in Cancer Diagnostics and Therapy: a recent update. Curr. Pharm. Des. 28, 471–487 (2022)
Article CAS PubMed Google Scholar
L.F. Sempere, A.S. Azmi, A. Moore, microRNA-based diagnostic and therapeutic applications in cancer medicine. Wiley Interdiscip Rev RNA 12, e1662 (2021)
Article CAS PubMed PubMed Central Google Scholar
K. Yamana, J. Inoue, R. Yoshida, J. Sakata, H. Nakashima, H. Arita, S. Kawaguchi, S. Gohara, Y. Nagao, H. Takeshita, M. Maeshiro, R. Liu, Y. Matsuoka, M. Hirayama, K. Kawahara, M. Nagata, A. Hirosue, R. Toya, R. Murakami, Y. Kuwahara, M. Fukumoto, H. Nakayama, Extracellular vesicles derived from radioresistant oral squamous cell carcinoma cells contribute to the acquisition of radioresistance via the mir-503-3p-BAK axis. J. Extracell. Vesicles. 10, e12169 (2021)
Article CAS PubMed PubMed Central Google Scholar
L. Fang, J. Cai, B. Chen, S. Wu, R. Li, X. Xu, Y. Yang, H. Guan, X. Zhu, L. Zhang, J. Yuan, J. Wu, M. Li, Aberrantly expressed mir-582-3p maintains lung cancer stem cell-like traits by activating Wnt/β-catenin signalling. Nat. Commun. 6, 8640 (2015)
Article CAS PubMed Google Scholar
Y. Zhang, X. Wang, Targeting the Wnt/β-catenin signaling pathway in cancer. J. Hematol. Oncol. 13, 165 (2020)
Article PubMed PubMed Central Google Scholar
A. Shams, R. Shabani, H. Asgari, M. Karimi, M. Najafi, M. Asghari-Jafarabadi, S.M. Razavi, S.R. Miri, M. Abbasi, A. Mohammadi, M. Koruji, In vitro elimination of EL4 cancer cells from spermatogonia stem cells by miRNA-143- and 206-loaded folic acid-conjugated PLGA nanoparticles. Nanomed. (Lond). 17, 531–545 (2022)
W. Du, R.E. Menjivar, K.L. Donahue, P. Kadiyala, A. Velez-Delgado, K.L. Brown, H.R. Watkoske, X. He, E.S. Carpenter, C.V. Angeles, Y. Zhang, M. Pasca di Magliano, WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer, J. Exp. Med., 220 (2023)
J. Wang, H. Yu, W. Dong, C. Zhang, M. Hu, W. Ma, X. Jiang, H. Li, P. Yang, D. Xiang, M6A-mediated upregulation of FZD10 regulates liver cancer stem cells properties and lenvatinib resistance through WNT/β-catenin and Hippo signaling pathways, Gastroenterology, (2023)
M.J. Parsons, T. Tammela, L.E. Dow, WNT as a driver and dependency in Cancer. Cancer Discov. 11, 2413–2429 (2021)
Article CAS PubMed PubMed Central Google Scholar
F. Yu, C. Yu, F. Li, Y. Zuo, Y. Wang, L. Yao, C. Wu, C. Wang, L. Ye, Wnt/β-catenin signaling in cancers and targeted therapies. Signal. Transduct. Target. Ther. 6, 307 (2021)
Article CAS PubMed PubMed Central Google Scholar
H.B. Park, J.W. Kim, K.H. Baek, Regulation of wnt signaling through Ubiquitination and Deubiquitination in Cancers, Int. J. Mol. Sci., 21 (2020)
D.J. Stewart, Wnt signaling pathway in non-small cell lung cancer. J. Natl. Cancer Inst. 106, djt356 (2014)
Z. Wu, W. Shi, C. Jiang, Overexpressing circular RNA hsa_circ_0002052 impairs osteosarcoma progression via inhibiting Wnt/β-catenin pathway by regulating miR-1205/APC2 axis. Biochem. Biophys. Res. Commun. 502, 465–471 (2018)
Article CAS PubMed Google Scholar
W. Zhang, X. Ruan, Y. Li, J. Zhi, L. Hu, X. Hou, X. Shi, X. Wang, J. Wang, W. Ma, P. Gu, X. Zheng, M. Gao, KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway. Theranostics. 12, 1500–1517 (2022)
Article CAS PubMed PubMed Central Google Scholar
F. Yang, H. Xiong, L. Duan, Q. Li, X. Li, Y. Zhou, MiR-1246 promotes Metastasis and Invasion of A549 cells by targeting GSK-3β–Mediated Wnt/β-Catenin pathway. Cancer Res. Treat. 51, 1420–1429 (2019)
Article CAS PubMed PubMed Central Google Scholar
C.L. Busceti, S. Marchitti, F. Bianchi, P. Di Pietro, B. Riozzi, R. Stanzione, M. Cannella, G. Battaglia, V. Bruno, M. Volpe, F. Fornai, F. Nicoletti, S. Rubattu, Dickkopf-3 upregulates VEGF in cultured human endothelial cells by activating activin receptor-like kinase 1 (ALK1) pathway. Front. Pharmacol. 8, 111 (2017)
Article PubMed PubMed Central Google Scholar
M.H. Soheilifar, M. Pornour, M. Saidijam, R. Najafi, F. Azizi Jalilian, H. Keshmiri Neghab, R. Amini, miR-1290 contributes to oncogenesis and angiogenesis via targeting of THBS1, DKK3 and, SCAI, Bioimpacts, 12, 349–358 (2022)
R. Kalluri, V.S. LeBleu, The biology, function, and biomedical applications of exosomes, Science, 367 (2020)
W. Yu, J. Hurley, D. Roberts, S.K. Chakrabortty, D. Enderle, M. Noerholm, X.O. Breakefield, J.K. Skog, Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann. Oncol. 32, 466–477 (2021)
Article CAS PubMed Google Scholar
Z. Zeng, Y. Li, Y. Pan, X. Lan, F. Song, J. Sun, K. Zhou, X. Liu, X. Ren, F. Wang, J. Hu, X. Zhu, W. Yang, W. Liao, G. Li, Y. Ding, L. Liang, Cancer-derived exosomal mir-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat. Commun. 9, 5395 (2018)
Article CAS PubMed PubMed Central Google Scholar
L. He, W. Zhu, Q. Chen, Y. Yuan, Y. Wang, J. Wang, X. Wu, Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostics. 9, 8206–8220 (2019)
Comments (0)